Sitero, a technology-enabled Clinical Research Organization (CRO), has significantly advanced its AI capabilities by acquiring the AI assets and business of studyOS, the creator of the Ash AI Clinical Trial Agent. This strategic move marks the launch of SiteroAI, positioning Sitero as a fully AI-enabled CRO and aiming to deliver substantial efficiency gains across the clinical development lifecycle for its customers.
Quick Intel
Sitero acquires the AI assets and business of eClinical provider studyOS.
The deal launches SiteroAI, an integrated AI platform for clinical trials.
SiteroAI targets 20-30% efficiency gains for customers in 2026.
The Ash AI agent uses natural language to optimize trial workflows.
studyOS CEO Ellis Butterfield joins Sitero as Chief Technology Officer (CTO).
The technology will be integrated into Sitero's Mentor eClinical platform.
With this acquisition, Sitero is launching SiteroAI to become what it terms the industry's first truly AI-enabled Clinical Research Organization. The integrated platform combines studyOS's Ash AI agent with Sitero's existing Mentor eClinical suite. This unified environment is designed to deliver significant, measurable improvements, with a projected 20-30% efficiency gain across the clinical development lifecycle for customers in 2026, directly impacting time-to-market and reducing overall study costs.
The core of the acquired technology is the Ash platform, an AI Clinical Trial Agent that uses a natural-language interface. This allows clinical teams to query, automate, and optimize trial workflows in real-time. The AI agent accelerates every phase of a trial, from initial study design and site activation through to data review, monitoring, and closeout, driving measurable efficiency gains in Data Management, Clinical Operations, and Sponsor Oversight.
The transaction is more than an asset purchase; it includes the integration of key studyOS technical and AI engineering personnel into Sitero. Ellis Butterfield, the CEO of studyOS, will assume the role of Chief Technology Officer at Sitero, ensuring a seamless transition and continuity of innovation. This strategic union is focused on scaling a powerful AI vision across the entire clinical trial spectrum, combining technology with deep operational expertise.
The acquisition of studyOS's AI assets represents a pivotal step in Sitero's mission to deeply integrate advanced technology with clinical research operations. By embedding a sophisticated AI agent directly into its eClinical platform, Sitero is not just adopting AI but is fundamentally redefining the clinical research execution model, offering sponsors a powerful tool to bring treatments to market faster and more efficiently.
Sitero is a next-generation clinical research partner supporting life sciences and institutional research organizations in bringing treatments to market safer and faster. Through a technology-forward approach, Sitero streamlines research, drives compliance, and unlocks innovation. With global offices in the US, UK, Canada, Poland, Australia, Mexico, and India, Sitero combines expert talent with agile execution across its clinical, regulatory, and safety service lines.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.